Menu Search
Equities

Sandoz Group AG

0SAN:LSE

Sandoz Group AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)40.18
  • Today's Change0.171 / 0.43%
  • Shares traded269.25k
  • 1 Year change+57.92%
  • Beta--
Data delayed at least 20 minutes, as of Nov 13 2024 17:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Sandoz Group AG had net income fall -90.92% from 848.00m to 77.00m despite a 7.23% increase in revenues from 9.31bn to 9.98bn. An increase in the cost of goods sold as a percentage of sales from 51.59% to 52.99% was a component in the falling net income despite rising revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, Sandoz Group AG increased its cash reserves by 1,398.65%, or 1.04bn. Cash Flow from Financing totalled 1.24bn or 12.45% of revenues. In addition the company generated 362.00m in cash from operations while cash used for investing totalled 614.00m.
Cash flow per share--
Price/Cash flow per share--
Book value per share17.16
Tangible book value per share-1.50
More ▼

Balance sheet in USDView more

Sandoz Group AG has a Debt to Total Capital ratio of 34.69%.
Current ratio1.22
Quick ratio0.7401
Total debt/total equity0.5313
Total debt/total capital0.3469
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		--
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.